GTO ID | GTC1863 |
Trial ID |
NCT03436771
|
Disease |
Multiple Myeloma
|
Mantle Cell Lymphoma
|
Non-Hodgkin's Lymphoma
|
Chronic Lymphocytic Leukemia
|
Follicular Lymphoma
|
Diffuse Large B-Cell Lymphoma
|
Altered gene | CD19|BCMA |
Therapeutic/Target gene | Target gene |
Therapy | CAR-T cell |
Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017;JCARH125|Orvacabtagene Autoleucel |
Location approved | US, Japan, EU, Switzerland, UK, Canada |
Generation | 2nd |
Recruitment status | Terminated |
Title | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product |
Year | 2018 |
Country | United States |
Company sponsor | Juno Therapeutics, a Subsidiary of Celgene |
Other ID(s) | LTFU001 |